

Supplemental Information

Table S1: Dose response conditions

Toxin	Class	Doses Tested (μM)	Mapping Concentration (μM)	Diluent
Cadmium	Heavy Metal	100, 200, 300, 400	100	Water
Carmustine	Chemotherapeutic	125, 250, 500, 1000	250	DMSO
Chlorothalonil	Pesticide	125, 250, 500, 1000	250	DMSO
Chlorpyrifos	Pesticide	0.25, 0.5, 1, 2	1	DMSO
Cisplatin	Chemotherapeutic	125, 250, 500, 1000	250	Water
Copper	Heavy Metal	625, 125, 250, 500	250	Water
Diquat	Pesticide	250, 500, 1000, 2000	250	Water
Fluoxetine	Neuropharmaceutical	625, 125, 250, 500	250	DMSO
FUdR	Chemotherapeutic	375, 50, 75, 100	50	Water
Irinotecan	Chemotherapeutic	625, 125, 250, 500	125	DMSO
Mechlorethamine	Chemotherapeutic	200, 300, 400, 500	200	DMSO
Paraquat	Pesticide	500, 1000, 2000, 4000	500	Water
Silver	Heavy Metal	75, 150, 300, 500	150	Water
Topotecan	Chemotherapeutic	50, 100, 200, 400	400	Water
Tunicamycin	Chemotherapeutic	5, 10, 15, 20	10	DMSO
Vincristine	Chemotherapeutic	20, 40, 60, 80	80	Water

Table S2: Principal components that explain 90% of phenotypic variation per toxin

Toxin	Number of Principal Components	Cumulative Variance Explained
Cadmium	6	90.93%
Carmustine	6	90.26%
Chlorothalonil	6	91.98%
Chlorpyrifos	7	91.60%
Cisplatin	6	90.75%
Copper	8	91.64%
Diquat	6	90.95%
Fluoxetine	7	90.09%
FUdR	7	91.47%
Irinotecan	5	92.78%
Mechlorethamine	7	91.93%
Paraquat	5	90.50%
Silver	5	92.41%
Topotecan	5	90.39%
Tunicamycin	5	93.28%
Vincristine	6	92.60%

Table S3: Power calculations

Number of replicates	Phenotypic variance explained (%) detectable with 80% power
23	38
46	21.9
69	15.3
92	11.7
115	9.5
138	8

Table S4: List of PCs mapped to each hotspot with NIL-assay tested toxins in bold

IV Left			IV Right			V		
Toxin	Trait	%VE	Toxin	Trait	%VE	Toxin	Trait	%VE
Carmustine	PC6	5.60	Chlorothalonil	PC3	10.88	Carmustine	PC1	7.00
Chlorothalonil	PC2	4.31	Chlorpyrifos	PC2	7.74	Chlorothalonil	PC1	15.35
Chlorothalonil	PC3	12.90	Cisplatin	PC3	2.68	Cisplatin	PC1	10.25
Chlorpyrifos	PC1	6.34	Fluoxetine	PC1	10.73	Cisplatin	PC4	7.18
Cisplatin	PC1	6.05	Fluoxetine	PC5	7.92	Irinotecan	PC2	6.78
Cisplatin	PC3	4.78	FUdR	PC3	5.54	Irinotecan	PC5	6.43
Copper	PC2	4.85	Irinotecan	PC2	5.49	Mechlorethamine	PC2	8.67
Copper	PC6	5.86	Vincristine	PC6	6.75	Paraquat	PC1	9.98
Fluoxetine	PC1	6.65				Silver	PC1	17.81
FUdR	PC3	5.54						
Silver	PC3	9.76						
Silver	PC4	9.28						
Silver	PC5	11.70						
Topotecan	PC2	9.70						
Tunicamycin	PC1	15.90						
Tunicamycin	PC3	6.70						
Vincristine	PC5	6.47						
Vincristine	PC6	6.75						

Reagents used to generate NILs and CSSs

Chromosome IVL NILs:

ECA229[*eanIR149*(IV:3,684,741-9,045,991, N2>CB4856)]

starting RIAL: QX275

ECA231[*eanIR151*(IV:4,475,146-9,334,865, CB4856>N2)]

starting RIAL: QX591

Left indel primers (IV: 5,110,734)

oECA781: GAGCACTTTGGCGACTTTTCG

oECA782: TCCGGGCAAATTAGTGTGGC

Right indel primers (IV: 8,212,089)

oECA857: CCACACGTCTACGCTTTGGA

oECA858: AATCGTGGCATTGGTGGACA

Chromosome IVR NILs:

ECA240[*eanIR160*(IV:12,865,211-17,493,829, CB4856>N2)]

starting RIAL: QX349

ECA241[*eanIR161*(IV:13,016,066-17,493,829, N2>CB4856)]

starting RIAL: QX375

Left indel primers (IV: 13,207,120)

oECA904: AACAGATACTCGCCGTTGCT

oECA905: ATTTGTACCACGCGTGACCT

Right indel primers (IV: 17,356,993)

oECA910: GACAACGCCCACTACGACAA

oECA911: ACCCAACCAGTTGAGCACAT

Chromosome V NILs:

ECA230[*eanIR150*(V:7,082,839-13,839,858, N2>CB4856)]

starting RIAL: QX131

ECA232[*eanIR152*(V:7,667,158-13,678,801, CB4856>N2)]

starting RIAL: QX450

Left indel primers (V: 7,862,556)

oECA799: TTCTCGCTACTGGAACACGC

oECA800: TCAAGAAGCGTTGGGAAGTCT

Right indel primers (V: 13,110,045)

oECA745: TGCAGAGGTGGAGTAACCCT

oECA746: CTCGGTCTCTCCCCACTAA

Chromosome V CSSs:

ECA554[*eanIR321*(V:1-20,924,180, N2>CB4856)]

ECA573[*eanIR322*(V:1-20,923,490, CB4856>N2)]

Left indel primers (V: 144,547)

oECA1141: CTCATGGGAGTAACCTGGGC

oECA1142: CGGTGACAACGGAGAATCCA

Right indel primers (V: 20,622,851)

oECA1147: GTTTAGTACCAGCGGGGCAT

oECA1148: TGCATTCCGACCCAAGAGAC

Background genotype confirmation primers for Chromosome V CSSs:

(I: 7,802,675)

oECA835: GTGGGTGGGAAGAAGCCTTT

oECA836: GCGTTGTGCAACCCAAAATG

(I: 14,736,165)

oECA631: GCTCAGCTCTTCACTTCCCA

oECA638: GTGCAATTGCGCAGGTAAGG

(II: 6,765,211)

oECA609: TTTCACACAAACCATGCGCT

oECA610: ACTCGTCTGCTGGGTATTCT

(II: 12,106,984)

oECA644: GGTCTGTCCAGTGTCCAGAA

oECA651: TCTGACAAGCGGCTTTCAGT

(III: 9,593,415)

oECA656: TGGCTGGGCATGGCTTAAA

oECA662: CGGGGTACTACACTATGGGG

(III: 6,040,736)

oECA655: GTTTGCATACACCAATGGCGA

oECA661: TGGAAGACGTGCTGAGATGG

(IV: 8,501,135)

oECA859: CTCGCTAATGGGTGAGCGAT

oECA860: TCCTGGAATCAACAACAGCA

(IV: 1,039,851)

oECA1132: ACAGGCGTTCAAAGACACCA

oECA1133: TGTCGAACAAGTGCCACAGT

(IV: 17,317,014)

oECA1135: TTTCAGACAGGAAAGCGCCT

oECA1136: GTTGAGAGATCCGGACCGAC

(V: 144,547)

oECA1141: CTCATGGGAGTAACCTGGGC

oECA1142: CGGTGACAACGGAGAATCCA

(V: 11,940,588)

oECA741: CCAGAATTTAGCATGCGTGGG

oECA742: AGTGTCTGGTTCCGTTAGTACT

(V: 20,622,851)

oECA1147: GTTTAGTACCAGCGGGGCAT

oECA1148: TGCATTCCGACCCAAGAGAC